A Phase II Study of Intensive Consolidation and Stem Cell Mobilization Therapy With Ofatumumab, Etoposide, and High-dose Ara-C (OVA), Followed by Autologous Stem Cell Transplantation in High-risk Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Latest Information Update: 01 Jul 2022
At a glance
- Drugs Cytarabine (Primary) ; Etoposide (Primary) ; Ofatumumab (Primary)
- Indications Diffuse large B cell lymphoma
- Focus Therapeutic Use
Most Recent Events
- 02 Jul 2021 Status changed from active, no longer recruiting to completed.
- 19 Apr 2019 Planned End Date changed from 1 Jun 2019 to 1 Jun 2022.
- 19 Apr 2019 Status changed from recruiting to active, no longer recruiting.